Brought to you by 
Synta Pharmaceuticals completes $50mm Series C round
17 Dec 2012
Executive Summary
Synta Pharmaceuticals (oncology and immunology drug discovery) has raised $50mm in its third round co-led by returning backers Caxton Group, Duquesne Capital, and Mountain Trail Investments. Gollust Management, Galleon Group, AIG SunAmerica, and other undisclosed institutional and individual investors also participated.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Synta Pharmaceuticals completes $50mm Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice